Chase Coleman III
Tiger Global Management
Chase Coleman III Novo Nordisk A/S stake
total: 436
Tiger Global Management NVO trades
- Total transactions:
- 3
- New positions:
- 1
- Sold out:
- 1
- Added:
- 1
- Held since:
- 2023 Q2
- Held for:
- 9 quarters
- Latest activity:
- 2025 Q3
According to 2026 Q2 report, Chase Coleman III doesn't hold any Novo Nordisk A/S (NVO) shares. To date, the estimated cost basis is nearly $126.39 for "buy" trades and estimated average "sell" price is $69.02. Tiger Global Management first purchased NVO in 2023 Q2, initially acquiring 634,500 shares. Since the initial investment in Novo Nordisk A/S (NVO), Tiger Global Management has made 2 more transactions.
When did Chase Coleman III sell Novo Nordisk A/S (NVO)?
Chase Coleman III sold off the entire Novo Nordisk A/S (NVO) position in 2025 Q3.
When did Chase Coleman III buy Novo Nordisk A/S (NVO)?
Chase Coleman III first invested in Novo Nordisk A/S (NVO) in 2023 Q2 at the reported quarter-end price of $161.83 per share.
What's the cost basis of Tiger Global Management's NVO stake?
The estimated cost basis for Novo Nordisk A/S (NVO) stake is around $126.39 per share. This represents their average reported price* across all buy transactions
Estimated cost basis*
- Weighted AVG buy price:
- $126.38
- Weighted AVG sell price:
- $69.02
Chase Coleman III's historical trades in Novo Nordisk A/S
3 results
| Period |
% of portfolio |
Shares held after* |
Reported price* |
Value* |
% (shares) of activity |
% change to portfolio |
|---|---|---|---|---|---|---|
|
2025 Q3
|
0.00%
|
0
|
$69.02
|
|
-100% (-1,269,000)
|
-0.26%
|
|
2023 Q3
|
0.85%
|
1,269,000
|
$90.94
|
$115,402,860
|
+100.00% (+634,500)
|
+0.43%
|
|
2023 Q2
|
0.86%
|
634,500
|
$161.83
|
$102,681,135
|
new
|
+0.86%
|
* Shares, change to shares, sold shares, shares held after: split-adjusted.
* Reported price: this doesn't represent the actual buy or sell price. It is the split-adjusted price of the security as of the last day of the reported period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
* Estimated cost basis: based on "Reported price*" (not earlier than 2013 Q2). Calculation starts from the latest "new buy" activity to the latest "close out" activity (if any).
* Value or Price: If the security is completely sold out, we show the reported value (or price) prior to the actual period.
* New buy or own: this means there is no earlier reporting (for us or in general). So we can't know if the actual purchase of the security happened at the reported period or earlier.